Medicines (Nov 2021)

Mortality of Patients Infected by COVID-19 with and without Deep-Vein Thrombosis

  • Jose Maria Pereira de Godoy,
  • Gleison Juliano da Silva Russeff,
  • Carolina Hungaro Costa,
  • Debora Yuri Sato,
  • Desirée Franccini Del Frari Silva,
  • Maria de Fatima Guerreiro Godoy,
  • Henrique Jose Pereira de Godoy,
  • Paulo César Espada

DOI
https://doi.org/10.3390/medicines8120075
Journal volume & issue
Vol. 8, no. 12
p. 75

Abstract

Read online

Background: Current evidence points to a state of hypercoagulability (consequence of hyperinflammation) as an important pathogenic mechanism that contributes to the increase in mortality in cases of COVID-19. The aim of the present study was to investigate the influence of deep-vein thrombosis on mortality patient’s infected with SARS-CoV-2. Method: A clinical trial was conducted involving 200 consecutive patients with COVID-19—100 patients who were positive for deep-vein thrombosis (venous Doppler ultrasound) and 100 who were negative for deep-vein thrombosis at a public hospital. Results: The mortality rate was 67% in the group positive for DVT and 31% in the group negative for DVT. Conclusion: Deep-vein thrombosis is associated with an increase in mortality in patients with COVID-19 and failures can occur with conventional prophylaxis for deep-vein thrombosis.

Keywords